Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

奥拉帕尼 前列腺癌 医学 癌症 肿瘤科 内科学 前列腺 临床试验 同源重组
作者
Maha Hussain,Claire Corcoran,Caroline Sibilla,Karim Fizazi,Fred Saad,Neal Shore,Shahneen Sandhu,Joaquin Mateo,David Olmos,Niven Mehra,Michael P Kolinsky,Guilhem Roubaud,Mustafa Özgüroǧlu,Nobuaki Matsubara,Craig Gedye,Doo Yong Chung,Charles Padua,Alexander Kohlmann,Robert Huisden,Julia A Elvin,Jinyu Kang,Carrie A Adelman,Allison Allen,Christian Poehlein,Johann Sebastian de Bono
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:28 (8): 1518-1530
标识
DOI:10.1158/1078-0432.ccr-21-3940
摘要

Successful implementation of genomic testing in clinical practice is critical for identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible for olaparib and future molecularly targeted therapies.An investigational clinical trial assay, based on the FoundationOneCDx tissue test, was used to prospectively identify patients with qualifying homologous recombination repair gene alterations in the phase III PROfound study. Evaluation of next-generation sequencing (NGS) tissue test outcome against preanalytic parameters was performed to identify key factors influencing NGS result generation.A total of 4,858 tissue samples from 4,047 patients were tested and reported centrally. NGS results were obtained in 58% (2,792/4,858) of samples (69% of patients). Of samples submitted, 83% were primary tumor samples (96% were archival and 4% newly obtained). Almost 17% were metastatic tumor samples (60% were archival and 33% newly obtained). NGS results were generated more frequently from newly obtained compared with archival samples (63.9% vs. 56.9%) and metastatic compared with primary samples (63.9% vs. 56.2%). Although generation of an NGS result declined with increasing sample age, approximately 50% of samples ages >10 years generated results. While higher tumor content and DNA yield resulted in greater success in obtaining NGS results, other factors, including selection and preservation of samples, may also have had an impact.The PROfound study shows that tissue testing to identify homologous recombination repair alterations is feasible and that high-quality tumor tissue samples are key to obtaining NGS results and identifying patients with mCRPC who may benefit from olaparib treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猪猪hero发布了新的文献求助10
刚刚
luo完成签到,获得积分10
2秒前
CY完成签到,获得积分10
3秒前
vtd完成签到 ,获得积分10
5秒前
CipherSage的应助被岁见采纳,获得10
5秒前
5秒前
SongXJ完成签到 ,获得积分10
9秒前
科研小白完成签到 ,获得积分10
9秒前
xwq完成签到,获得积分10
10秒前
KINGAZX完成签到 ,获得积分10
12秒前
漾漾的羊完成签到 ,获得积分10
17秒前
新帅完成签到,获得积分10
18秒前
arniu2008发布了新的文献求助10
26秒前
26秒前
黑米粥发布了新的文献求助30
29秒前
Waiting完成签到 ,获得积分10
29秒前
33秒前
复杂芷文完成签到,获得积分10
34秒前
MM完成签到 ,获得积分10
34秒前
ty完成签到 ,获得积分10
36秒前
猪猪hero完成签到,获得积分10
37秒前
潮哥完成签到 ,获得积分10
38秒前
岁见发布了新的文献求助10
41秒前
秀丽颤完成签到,获得积分10
43秒前
43秒前
44秒前
Harlotte完成签到 ,获得积分0
46秒前
慕青的应助被霖29采纳,获得10
46秒前
黑米粥发布了新的文献求助200
47秒前
49秒前
cloud完成签到 ,获得积分10
51秒前
李健的应助被岁见采纳,获得10
52秒前
酷酷的幼菱完成签到 ,获得积分10
53秒前
57秒前
黑米粥发布了新的文献求助200
57秒前
月昔完成签到 ,获得积分10
58秒前
isedu完成签到,获得积分0
59秒前
大方碧完成签到,获得积分10
1分钟前
bkagyin的应助被科研通管家采纳,获得10
1分钟前
霖29发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185501
求助须知:如何正确求助?哪些是违规求助? 9574179
关于积分的说明 21834528
捐赠科研通 7783108
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481357